πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

299 results for β€œAVI” Clear

  1. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Ophthalmics Europe

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  3. Pozelimab + Cemdisiran

    Regeneron UK Limited

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. RHB-204

    RedHill Biopharma

    Pulmonary Mycobacterium Avium Complex Infection

    phase 3 small molecule terminated

    1 trial

  5. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  6. Recombinant 14-Valent Human Papillomavirus Vaccine（Insect CellοΌ‰

    China SXT Pharmaceuticals

    HPV InfectioN

    phase 3 mab active

    1 trial

  7. Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papillomavirus Infection

    phase 3 mab active

    1 trial

  8. Ribavirin

    Vertex Pharmaceuticals (Ireland) Limited

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  9. Rituximab

    First Tracks Biotherapeutics

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare BV

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  11. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial

  12. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  13. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  14. Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  15. Standard of Care Treatment

    Kyverna Therapeutics

    Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences International Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  17. TAK-019

    Takeda Pharmaceuticals International AG

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  18. TENOFOVIR DISOPROXIL , ENTECAVIR , VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR ALAFENAMIDE

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  19. TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN

    Disc Medicine

    Respiratory tract infection

    phase 3 small molecule active

    1 trial

  20. Tacrolimus capsule

    China SXT Pharmaceuticals

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  21. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  22. Topiramate + Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule active

    1 trial

  23. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  24. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources